EcoR1 Capital’s Corvus Pharmaceuticals CRVS Stock Holding History

EcoR1 Capital’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,081,077	Closed	-$10.1M	–	80
2021 Q3	$10.1M	Sell	2,081,077 -1,498,300	-42%	-$4.43M	0.35%	33
2021 Q2	$9.56M	Buy	+3,579,377	New	+$9.85M	0.36%	33
2020 Q3	–	Sell	-737,612	Closed	-$2.01M	–	52
2020 Q2	$2.01M	Hold	737,612	–	–	0.15%	42
2020 Q1	$1.56M	Hold	737,612	–	–	0.16%	40
2019 Q4	$4.01M	Buy	+737,612	New	+$2.58M	0.36%	37
2019 Q1	–	Sell	-295,420	Closed	-$1.08M	–	46
2018 Q4	$1.08M	Sell	295,420 -55,981	-16%	-$382K	0.11%	48
2018 Q3	$3.02M	Sell	351,401 -98,999	-22%	-$990K	0.27%	42
2018 Q2	$4.95M	Sell	450,400 -19,300	-4%	-$215K	0.47%	28
2018 Q1	$5.42M	Sell	469,700 -118,732	-20%	-$1.12M	0.54%	28
2017 Q4	$6.1M	Sell	588,432 -320,093	-35%	-$4.1M	0.69%	21
2017 Q3	$14.5M	Buy	908,525 +103,525	+13%	+$1.43M	1.93%	14
2017 Q2	$9.74M	Buy	+805,000	New	+$8.59M	1.73%	14

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

EcoR1 Capital's CRVS Position: Q4 2021 in Review

EcoR1 Capital sold out of Corvus Pharmaceuticals (CRVS) in Q4 2021, closing a stake of 2,081,077 shares — an estimated $10.1M sold.

EcoR1 Capital first reported a position in CRVS in Q2 2017 and held it in 12 quarters. The position peaked at $14.5M in Q3 2017. 62 funds tracked by Wall St. Rank hold CRVS as of Q4 2021.

EcoR1 Capital reported no remaining Corvus Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
EcoR1 Capital sold 2,081,077 Corvus Pharmaceuticals shares in Q4 2021, an estimated $10.1M.
EcoR1 Capital first reported a position in Corvus Pharmaceuticals in Q2 2017 and held it in 12 quarters.
EcoR1 Capital's Corvus Pharmaceuticals position peaked at $14.5M in Q3 2017.
62 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2021.

Based on EcoR1 Capital's 13F filing for Q4 2021, filed 14 Feb 2022.